COLORADO SPRINGS, Colo.,
March 20, 2015 /PRNewswire/ -- Cannabis Science, Inc.
(OTCQB: CBIS), a U.S. company specializing in cannabis
formulation-based drug development and
related consulting, today announced that accomplished
scholar, epidemiologist, and public health physician Allen A. Herman, M.B., Ch.B., Ph.D. has joined
its scientific advisory board.
Dr. Herman, while serving as a project officer and program
director at the National Institutes of Health (NIH) designed the
basis for a nationwide $160 million
infant mortality reduction program and was the co-director of joint
projects between the NIH and the Centers for Disease Control and
Prevention (CDC). His work as the scientific director of a
$25 million NIH Infant Mortality
Reduction research program defined much of the basis for much of
the current community-based maternal and child health public health
work designed to provide a healthy start for families. For his work
in maternal and child health Dr. Herman received the National
Institutes Award of Merit. In addition to his work on maternal and
child health, Dr. Herman was a member of the World Mental Health
Survey team and helped design and execute the South African Stress
and Health Study, the largest mental health survey in Africa.
He was the founding Dean of the Republic of South Africa's National School of Public
Health. Dr. Herman also served as scientific advisor to then
deputy-president (and now president) of the Republic of
South Africa, Jacob Zuma and the South African Minister of
Defense in the design and execution of a substantial HIV/AIDS
treatment program for the South African National Defense Force. Dr.
Herman and Mr. Dellums secured $100
million from Bristol-Myers Squibb. These funds were used to
develop the 'Secure the Future' project, a research and scientific
development program in southern Africa. Dr. Herman served as a Principal
Investigator and on the Scientific Advisory Board of 'Secure the
Future'.
Dr. Herman was also the Advisor to Ronald V. Dellums, who served President
Bill Clinton as the Chairman of the
U.S. Presidential Committee on HIV/AIDS. In this capacity, Dr.
Herman, Mr. Dellums and Congresswoman Barbara Lee (the founding co-chair of the
Congressional HIV/AIDS Caucus) developed the successful
congressional legislation for the "AIDS Marshall Plan for
Africa" which formed the basis of
the President's Emergency Plan for AIDS Relief (PEPFAR). For his
work in HIV/AIDS, Dr. Herman received the 'Heroes in Medicine'
award from the International Association of Physicians in AIDS
Care.
Dr. Herman will report directly to the President & CEO, Mr.
Raymond C. Dabney to assist him in
tracking and monitoring the multiple international drug development
programs the company has underway. Because of Dr. Herman's
expertise in international healthcare management and physician and
health professional continuing education he will be key to assist
Mr. Dabney on a daily basis to report to the public the Company's
scientific progress and accomplishments.
"This is an exciting opportunity for me to work closely with Mr.
Dabney and the CBIS Team. I look forward to assisting the team with
a strong educational based tracking system focused on developing
promising pharmaceutical products and delivery mechanisms that have
the potential to help many patients with many critical ailments
around the world," said Dr. Herman. "The promise is as huge as the
need, worldwide."
"We now have yet another cornerstone that will help us take the
company to the next level. Dr. Herman will join our well-respected
and accomplished team of pharmaceutical drug development
specialists. We are growing so fast that Dr. Herman's main duty
will be to report our international activities as one, so the team
is up to speed and working closely as one unit as we grow
exponentially," stated, Mr. Dabney.
Please click here to review Dr. Herman's full CV:
http://www.cannabisscience.com/about-cbis/leadership/scientific-advisory-board
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique
understanding of metabolic processes to provide novel treatment
approaches to a number of illnesses for which current treatments
and understanding remain unsatisfactory. Cannabinoids have an
extensive history dating back thousands of years, and currently,
there are a growing number of peer-reviewed scientific publications
that document the underlying biochemical pathways that cannabinoids
modulate. The Company works with leading experts in drug
development, medicinal characterization, and clinical research to
develop, produce, and commercialize novel therapeutic approaches
for the treatment for illnesses caused by infections as well as for
age-related illness. Our initial focus is on skin cancers,
HIV/AIDS, and neurological conditions. The Company is
proceeding with the research and development of its proprietary
drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1,
and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc., does not undertake any duty nor does it intend to
update the results of these forward-looking statements. Safe Harbor
Statement. The Private Securities Litigation Reform Act of
1995 provides a 'safe harbor' for forward-looking statements.
Certain of the statements contained herein, which are not
historical facts are forward looking statements with respect to
events, the occurrence of which involved risks and
uncertainties. These forward-looking statements may be
impacted, either positively or negatively, by various
factors. Information concerning potential factors that could
affect the company are detailed from time to time in the company's
reports filed with the Securities and Exchange Commission.
Media Contacts:
VAN STONE PUBLICITY
Carrol Van
Stone
carrol@vanstonepublicity.com
Tel: 304-671-0244
Cannabis Science, Inc.
Raymond
C. Dabney
President & CEO, Co-Founder
info@cannabisscience.com
Tel: 1.888.889.0888
Chad S. Johnson, Esq.
Director, COO & General Counsel
info@cannabisscience.com
Tel: 1.888.889.0888
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/former-national-institute-of-health-nih-scientist-allen-a-herman-mb-chb-phd-joins-the-cannabis-science-scientific-advisory-board-sab-300053689.html
SOURCE Cannabis Science, Inc.